Clinical

GLP-1 and Testosterone: Does Weight Loss Actually Raise Your T?

· 7 min read

The question every guy on a GLP-1 asks eventually: what's this doing to my testosterone? The short answer — backed by data presented at ENDO 2025 and multiple clinical studies — is that GLP-1 therapy typically raises testosterone in men with obesity. But the mechanism isn't what most people assume, and the size of the effect depends on how much fat you lose.

The Aromatase Problem

Here's why obese men tend to have low testosterone, and it's not complicated. Adipose tissue (body fat) contains an enzyme called aromatase. Aromatase converts testosterone into estradiol — a form of estrogen. The more fat you carry, the more aromatase activity, the more testosterone gets converted into estrogen. This creates a cascade:

Elevated estrogen signals the hypothalamus to suppress GnRH release. Suppressed GnRH means less luteinizing hormone (LH). Less LH means the testes produce less testosterone. Meanwhile, insulin resistance — which almost always accompanies obesity — further impairs Leydig cell function and HPG axis signaling. Chronic inflammation from adipose tissue adds another layer of suppression.

The clinical term for this is functional hypogonadism — testosterone deficiency caused by comorbidities rather than primary testicular failure. It's extremely common in obese men and widely underdiagnosed.

What the Data Shows

Multiple studies now confirm that GLP-1-mediated weight loss raises testosterone in men who start with obesity-related low T:

ENDO 2025 (110 men, 18 months). Researchers tracked men using semaglutide, tirzepatide, or dulaglutide. At baseline, only 53% had testosterone in the normal range. After 18 months of GLP-1 therapy and approximately 10% body weight loss, 77% had normal testosterone — without any testosterone replacement therapy. Average total testosterone increased roughly 18%.

2024 Slovenian RCT (semaglutide vs. TRT). In obese diabetic men with hypogonadism, semaglutide produced a 1.6 nmol/L increase in total testosterone with just 6.5% weight loss. The study directly compared semaglutide to testosterone replacement therapy and found semaglutide was actually superior for body composition while matching TRT on testosterone improvement.

2025 Italian pilot (tirzepatide vs. TRT vs. lifestyle, 83 men, 8 weeks). Tirzepatide produced larger increases in both free and total testosterone than transdermal TRT, along with better body composition and erectile function. The lead researcher described tirzepatide as a candidate for first-line management of metabolic hypogonadism.

The Key Distinction: Indirect, Not Direct

GLP-1 medications do not directly stimulate the testes to produce more testosterone. There's no receptor-level interaction with androgen production pathways. The testosterone increase is entirely indirect — it's a downstream consequence of fat loss.

Less fat → less aromatase → less testosterone-to-estrogen conversion → the HPG axis comes back online → the testes resume normal production. Additionally, improved insulin sensitivity and reduced inflammation both support hormonal signaling.

This distinction matters because it means the testosterone benefit is proportional to fat loss. Men who lose 5% of body weight will see modest improvements. Men who lose 15%+ will see much larger effects. And men who were already lean with low T for non-obesity reasons shouldn't expect GLP-1 therapy to fix it.

The Catch: Men Lose Less Weight on GLP-1s

There's a frustrating reality in the clinical data: women consistently lose more weight on GLP-1 therapy than men. In the STEP trials, the treatment difference versus placebo was 14.0% in women versus 8.0% in men (STEP 1), and 16.2% versus 9.3% (STEP 4). The reasons aren't fully understood but likely involve differences in baseline body composition, hormonal milieu, and eating behavior patterns.

This doesn't mean GLP-1s don't work for men — they clearly do. But it means the magnitude of secondary benefits like testosterone recovery may be more modest in men who achieve less total weight loss.

GLP-1 vs. TRT: The Practical Question

For men with obesity-related low T, the emerging evidence suggests GLP-1 therapy may be a better first-line approach than jumping straight to testosterone replacement. Here's why:

TRT treats the symptom (low T) without addressing the cause (excess fat). GLP-1 therapy addresses the cause, and the testosterone recovery comes as a bonus. TRT also carries its own baggage: potential fertility suppression, cardiovascular monitoring requirements, injection schedules, and the psychological loop of dependence on exogenous hormones.

That said, this is a clinical decision that depends on your specific situation. If your testosterone is critically low and causing immediate symptoms, waiting months for GLP-1-mediated weight loss may not be practical. Some clinicians are now combining short-term TRT with GLP-1 therapy, then tapering TRT as weight loss improves natural production.

Talk to your prescriber. Get baseline bloodwork before starting GLP-1 therapy. Repeat at 3 and 6 months. Track the trajectory.

Bottom Line

GLP-1 medications don't directly boost testosterone — but in men with obesity, the weight loss they produce typically does. The data from ENDO 2025, head-to-head comparisons with TRT, and mechanistic studies all point in the same direction: lose the fat, recover the T. It's not guaranteed, it's not immediate, and it's not a substitute for clinical evaluation. But for the millions of men whose low testosterone is driven by excess body fat, GLP-1 therapy may fix two problems at once.

Compare Men's GLP-1 Providers

See pricing, intake process, and available medications from telehealth providers.

View Providers →

Sources